Delafloxacin is an anionic fluoroquinolone (FQ) antibiotic, with a good safety profile, active against both Gram positive and negative bacteria, including Methicillin-resistant Staph. aureus (MRSA) and FQs resistant strains.
Based on the clinical results, delafloxacin could be an excellent treatment option for patients with comorbidities, at higher risk of infections by difficult-to-treat microorganisms, like MRSA and multi resistant Gram negative strains, which cause recurrent infections, poor patient outcomes and higher use of healthcare resources.
During the clinical development, delafloxacin demonstrated a good safety and tolerability profile, with improved characteristics in comparison to other antibiotics of this class (absence of QT-prolongation and phototoxicity).
Delafloxacin has been approved by FDA and EMA for the indication of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). A phase IIIb study is currently ongoing in a sub-population of ABSSSI patients with Surgical Site Infections (SSI).
Furthermore, a global phase III registrational trial in hospitalized patients with Community Acquired Bacterial Pneumonia (CABP) has been recently completed and the marketing authorization for CABP has been submitted to EMA.
VISIT OUR CLINICAL TRIALS DATABASE